Development of the Near Vision Presbyopia Task-based Questionnaire for use in evaluating the impact of presbyopia

Shirneshan, Elaheh; Coon, Cheryl D.; Johnson, Nathan; Stokes, Jonathan; Wells, Ted; Lundy, J. Jason; Andrae, David A.; Evans, Christopher J.; Campbell, Joanna

doi:10.1186/s41687-021-00378-y

Journal of Patient-Reported Outcomes

Table 2 Participants’ vision-related information

From: Development of the Near Vision Presbyopia Task-based Questionnaire for use in evaluating the impact of presbyopia

	Concept elicitation interviews (N = 20)		Cognitive debriefing interviews (N = 20)
Uncorrected near-vision acuity in both eyes, n (%)^a
20/39 or better^a	0 (0)		3 (15.0)
20/40–20/59	14 (70.0)		11 (55.0)
20/60–20/79	2 (10.0)		4 (20.0)
20/80 or worse	3 (15.0)		2 (10.0)
Data unavailable	1 (5.0)		0 (0)
Uncorrected near-vision acuity in the right eyes, n (%)
20/39 or better^b	0 (0)		1 (5.0)
20/40–20/59	13 (55.0)		12 (60.0)
20/60–20/79	2 (10.0)		5 (25.0)
20/80 or worse	4 (20.0)		2 (10.0)
Data unavailable	1 (5.0)		0 (0)
Uncorrected near-vision acuity in the left eyes, n (%)
20/39 or better^b	0 (0)		1 (5.0)
20/40–20/59	14 (70.0)		11 (55.0)
20/60–20/79	3 (15.0)		3 (15.0)
20/80 or worse	2 (10.0)		5 (25.0)
Data unavailable	1 (5.0)		0 (0)
Average time (SD) with near-vision difficulty, y	7.6 (8.4)		7.5 (8.8)
Range	1–36		0.5–37
Near-vision treatment experience, n (%)^c	Current	Past	Current	Past
Prescription reading glasses	10 (50.0)	3 (15.0)	13 (65.0)	1 (5.0)
OTC reading glasses	8 (40.0)	0 (0)	18 (90.0)	0 (0)
Magnifying glasses	9 (45.0)	1 (5.0)	2 (10.0)	0 (0)
Prescription glasses for distance vision	7 (35.0)	1 (5.0)	1 (5.0)	1 (5.0)
Prescription bifocals	5 (25.0)	1 (5.0)	3 (15.0)	0 (0)
Prescription progressive glasses	5 (25.0)	0 (0)	2 (10.0)	0 (0)
Contact lenses for near vision	0 (0)	2 (10.0)	0 (0)	1 (5.0)
Contact lenses for distance vision	1 (5.0)	1 (5.0)	0 (0)	0 (0)
No treatment	2 (10.0)	0 (0)	0 (0)	0 (0)
Prescription trifocals	0 (0)	0 (0)	1 (5)	0 (0)
Time (SD) using near-vision treatment, y
OTC reading glasses	5.3 (1.9)		4.0 (4.0)
Range	3.0, 8.0		0.1, 16.0
n	6		18
Prescription glasses	5.1 (6.7)		5.6 (6.2)
Range	0.4, 20.0		0.6, 20.0
n	8		12
Prescription bifocals	3.5 (3.9)		7.0 (7.0)
Range	0.1, 8.8		2.0, 15.0
n	4		3
Other	6.1 (7.9)		6.8 (7.4)
Range	0.2, 15.0		1.5, 12.0
n	3^d		2^e
Time (SD) using distance-vision treatment, y
Prescription glasses	11.2 (13.7)		1.5 (NA)
Range	0.2, 41.4		NA
n	9		1
Prescription bifocals	4.3 (4.3)		8.5 (9.2)
Range	0.1, 8.8		2.0, 15.0
n	3		2
Contact lenses	7.0 (NA)		0
Range	NA		0
n	1		0
Other	0		1.0 (NA)
Range	0		NA
n	0		1^e

NA, not applicable; OTC, over-the-counter; SD, standard deviation; y, year
^aIncluded 2 cognitive debriefing interview participants who had uncorrected visual acuity of 20/40 or worse in each eye separately (per the eligibility criteria), and 20/39 or better in both eyes. One cognitive debriefing interview participant had uncorrected visual acuity of 20/39 or better in both eyes and in each eye separately, and thus did not meet the eligibility criteria; however, this participant was included in analysis in error
^bRefers to 1 of 2 participants with uncorrected visual acuity of 20/40 or worse in each eye separately (per the eligibility criteria), and 20/39 or better in both eyes
^cReflects all treatments that applied to each participant, as reported in their demographic information form and during their interview
^dIncluded prescription progressive glasses (n = 2, 10.0%) and “target shooting” glasses (n = 1, 5.0%)
^eDetails were not collected during the cognitive debriefing interviews

Back to article page